Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
1Университет им. Давида Бен-Гуриона в Негеве. 8410501, Израиль, Беер-Шева; 2ФГБОУ ВО «Ставропольский государственный медицинский университет» Минздрава России. 355017, Россия, Ставрополь, ул. Мира, д. 310 yubykov@gmail.com
Список исп. литературыСкрыть список 1. Авакян Г. Ламотриджин в лечении эпилепсии у женщин. Врач. 2007; 5: 44–7. / Avakian G. Lamotridzhin v lechenii epilepsii u zhenshchin. Vrach. 2007; 5: 44–7. [in Russian] 2. Авакян Г.Н., Юдельсон Я.Б., Маслова Н.Н., Гусев Е.И. Патогенез и лечение эпилепсии. /Журн. невропатологии и психиатрии. 2003; 9: 9–15. / Avakyan G.N., Iudel'son Ia.B., Maslova N.N., Gusev E.I. Patogenez i lechenie epilepsii. /Zhurn. nevropatologii i psikhiatrii. 2003; 9: 9–15. [in Russian] 3. Баранов П.А., Апполонова С.А. и др. Влияние мексидола на соотношение 6-бета-гидроксикортизол/свободный кортизол. Возможная индукция CYP 3A4. Эксперимент. и клин. фармакология. 2010; 73 (11): 39–40. / Baranov P.A., Appolonova S.A. i dr. Vliianie meksidola na sootnoshenie 6-beta-gidroksikortizol/svobodnyi kortizol. Vozmozhnaia induktsiia CYP 3A4. Eksperiment. i klin. farmakologiia. 2010; 73 (11): 39–40. [in Russian] 4. Бурчинский С.Г. Антиконвульсанты в фармакотерапии биполярных расстройств. Междунар. неврологический журн. 2010; 6: 110–5. / Burchinskii S.G. Antikonvul'santy v farmakoterapii bipoliarnykh rasstroistv. Mezhdunar. nevrologicheskii zhurn. 2010; 6: 110–5. [in Russian] 5. Бурчинский С.Г. Антиконвульсанты нового поколения и стандарты монотерапии эпилепсии. Междунар. неврологический журн. 2007; 6 (16). / Burchinskii S.G. Antikonvul'santy novogo pokoleniia i standarty monoterapii epilepsii. Mezhdunar. nevrologicheskii zhurn. 2007; 6 (16). [in Russian] 6. Мухин К.Ю., Пылаева О.А., Миронов М.Б. Эффективность и переносимость Ламитора (Ламотриджин) в лечении идиопатических фокальных и генерализованных форм эпилепсии в монотерапии и политерапии детей и подростков. Рус. журн. детской неврологии. 2013; VIII (1): 3–12. / Mukhin K.Iu., Pylaeva O.A., Mironov M.B. Effektivnost' i perenosimost' Lamitora (Lamotridzhin) v lechenii idiopaticheskikh fokal'nykh i generalizovannykh form epilepsii v monoterapii i politerapii detei i podrostkov. Rus. zhurn. detskoi nevrologii. 2013; VIII (1): 3–12. [in Russian] 7. Ламиктал. Официальная инструкция к препарату. Опубликовано в справочнике Видаль (https://www.vidal.ru/drugs/ lamictal__18625). / Lamiktal. Ofitsial'naia instruktsiia k preparatu. Opublikovano v spravochnike Vidal' (https://www.vidal.ru/drugs/ lamictal__18625). [in Russian] 8. Нурмухаметова С.Р., Магжанов Р.В. Опыт применения ламотриджина при лечении эпилепсии у пожилых. Эпилепсия и пароксизмальные состояния. 2013; 5 (1): 48–50. / Nurmukhametova S.R., Magzhanov R.V. Opyt primeneniia lamotridzhina pri lechenii epilepsii u pozhilykh. Epilepsiia i paroksizmal'nye sostoianiia. 2013; 5 (1): 48–50. [in Russian] 9. Сариев А.К., Жердев В.П., Литвин А.А. и др. Кинетика выведения мексидола и его глюкуроноконъюгата с мочой больных. Эксперим. и клин. фармакология. 1999; 62 (5): 42–6. / Sariev A.K., Zherdev V.P., Litvin A.A. i dr. Kinetika vyvedeniia meksidola i ego gliukuronokon"iugata s mochoi bol'nykh. Eksperim. i klin. farmakologiia. 1999; 62 (5): 42–6. [in Russian] 10. Сариев А.К. Фармакокинетика производных 3-оксипиридина в эксперименте. Дис. … канд. мед. наук. М., 1987. / Sariev A.K. Farmakokinetika proizvodnykh 3-oksipiridina v eksperimente. Dis. … kand. med. nauk. M., 1987. [in Russian] 11. Харламов Д.А., Зенков Л.Р., Сарапулова А.А. и др. Ламотриджин в лечении фармакорезистентной эпилепсии у детей. Неврологический журн. 2003; 8 (4): 30. / Kharlamov D.A., Zenkov L.R., Sarapulova A.A. i dr. Lamotridzhin v lechenii farmakorezistentnoi epilepsii u detei. Nevrologicheskii zhurn. 2003; 8 (4): 30. [in Russian] 12. Якушева Е.Н., Щулькин А.В., Черных И.В. Оценка принадлежности мексидола к субстратам, ингибиторам или индукторам гликопротеина-Р. Эксперим. и клин. фармакология. 2015; 78 (5): 19–23. / Iakusheva E.N., Shchul'kin A.V., Chernykh I.V. Otsenka prinadlezhnosti meksidola k substratam, ingibitoram ili induktoram glikoproteina-R. Eksperim. i klin. farmakologiia. 2015; 78 (5): 19–23. [in Russian] 13. Ackers R, Murray ML, Besag F et al. Prioritizing children's medicines for research: a pharmacoepidemiological study of antiepileptic drugs. Br J Clin Pharmacol 2007; 63: 689–97. 14. Alabi A, Todd A, Husband A, Reilly J. Safety profile of lamotrigine in overdose. Ther Adv Psychopharmacol 2016; 6 (6): 369–81. 15. Allain H, Schück S, Nachit-Ouinekh F et al. Improvement in quality of life after initiation of lamotrigine therapy in patients with epilepsy in a naturalistic treatment setting. Seizure 2007; 16 (2): 173–84. 16. Barbosa L, Berk M, Vorster M. A double-blind, randomized, placebo-controlled trial of augmentation with lamotrigine or placebo in patients concomitantly treated with fluoxetine for resistant major depressive episodes. J Clin Psychiatry 2003; 64: 403–7. 17. Betchel NT, Saadabadi A. Lamotrigine. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing, 2018. 18. Betts T, Yarrow H, Dutton N et al. A study of anticonvulsant medication on ovarian function in a group of women with epilepsy who have only ever taken on anticonvulsant compared with a group of women without epilepsy. Seizure 2003; 12: 323–9. 19. Beynon S, Soares-Weiser K, Woolacott N et al. Pharmacological interventions for the prevention of relapse in bipolar disorder: a systematic review of controlled trials. J Psychopharmacol 2009; 23: 574–91. 20. Binnie CD, van Emde Boas W, Kasteleijn-Nolste-Trenite DG et al. Acute effects of lamotrigine (BW430C) in persons with epilepsy. Epilepsia 1986; 27: 248–54. 21. Biton V, Sackellares JC, Vuong A et al. Double-blind, placebo-controlled study of lamotrigine in primary generalized tonic-clonic seizures. Neurology 2005; 65: 1737–43. 22. Biton V. Pharmacokinetics, toxicology and safety of lamotrigine in epilepsy. Expert Opin Drug Metab Toxicol 2006; 2 (6): 1009–18. 23. Bowden CL, Calabrese JR, Sachs G et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 2003; 60: 392–400. 24. Bowden CL, Singh V. Lamotrigine (Lamictal IR) for the treatment of bipolar disorder. Expert Opin. Pharmacother 2012; 13 (17): 2565–71. 25. Bowden CL, Calabrese JR, Sachs G et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 2003; 60 (4): 392–400. 26. Bowden CL. Acute and maintenance treatment with mood stabilizers. Int J Neuropsychopharmacol 2003; 6: 269–75. 27. Brodie MJ, Richens A, Yuen AW. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet 1995; 345: 476–9. 28. Brodie MJ. Lamotrigine. Lancet 1992; 339: 1397–400. 29. Calabrese JR et al. A double-blind, placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. J Clin Psychiat 1999; 60: 79–88. 30. Calabrese JR, Bowden CL, Sachs G et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry 2003; 64: 1013–24. 31. Calabrese JR, Huffman RF, White RL et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Dis 2008; 10: 323–33. 32. Celebi A, Yalnmzoglu D, Turanli G et al. Lamotrigine in children with refractory epilepsy. Turk J Pediatr 2008; 5054: 26–31. 33. Christensen J, Petrenaite V, Atterman J et al. Oral contraceptives induce lamotrigine metabolism: evidence fr om a double-blind, placebo-controlled trial. Epilepsia 2007; 48 (3): 484–9. 34. Cohen AF, Land GS, Breimer DD et al. Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans. Clin Pharmacol Ther 1987; 42: 535–41. 35. Coulter DA. Antiepileptic drug cellular mechanisms of action: wh ere does lamotrigine fit in? J Child Neurol 1997; 12 (Suppl. 1): S2–S9. 36. Duchowny M, Pellock JM, Graf WD et al. A placebo-controlled trial of lamotrigine add-on therapy for partial seizures in children. Lamictal Pediatric Partial Seizure Study Group. Neurology 1999; 53 (8): 1724–31. 37. Ebert U, Thong NQ, Oertel R et al. Effects of rifampicin and cimetidine on pharmacokinetics and pharmacodynamics of lamotrigine in healthy subjects. Eur J Clin Pharmacol 2000; 56: 299–304. 38. Ebrahimi HA, Ebrahimi F. The effect of lamotrigine on epilepsy. Iran J Neurol 2012; 11 (4): 162–3. 39. Eriksson AS, Knutsson E, Nergårdh A. The effect of lamotrigine on epileptiform discharges in young patients with drug-resistant epilepsy. Epilepsia 2001; 42 (2): 230–6. 40. Eriksson AS, Nergårdh A, Hoppu K. The efficacy of lamotrigine in children and adolescents with refractory generalized epilepsy: a randomized, double-blind, crossover study. Epilepsia 1998; 39 (5): 495–501. 41. EURAP Study Group. Seizure control and treatment in pregnancy: observations from the EURAP epilepsy pregnancy registry. Neurology 2006; 66: 354–60. 42. Fountoulakis KN, Vieta E. Treatment of bipolar disorder: a systematic review of available data and clinical perspectives. Int J Neuropsychopharmacol 2008; 11: 999–1029. 43. Frye M et al. Previous episode burden and response to treatment in bipolar I disorder. Am Psychiat Ass Ann Meet 2003; p. 165. 44. Frye MA, Ketter TA, Kimbrell TA et al. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol 2000; 20: 607–14. 45. Gamble C, Williamson PR, Chadwick DW, Marson AG. A meta-analysis of individual patient responses to lamotrigine or carbamazepine monotherapy. Neurology 2006; 66 (9): 1310–7. 46. Gamble CL, Williamson PR, Marson AG. Lamotrigine versus carbamazepine monotherapy for epilepsy. Cochrane Database Syst Rev 2006; 1: CD001031. 47. Gilliam F, Vazquez B, Sackellares J et al. An active-control trial of lamotrigine monotherapy for partial seizures. Neurology 1998; 51: 1018–25. 48. Goa K, Ross SR, Chrisp P. Lamotrigine. A review of its pharmacological properties and clinical efficacy in epilepsy. Drugs 1993; 46: 152–76. 49. Goldenberg M. Overview of drugs used for epilepsy and seizures: etiology, diagnosis, and treatment. P T 2010; 35 (7): 392–415. 50. Goldsmith DR, Wagstaff AJ, Ibbotson T, Perry CM. Spotlight on lamotrigine in bipolar disorder. CNS Drugs 2004; 18 (1): 63–7. 51. Goldsmith DR, Wagstaff AJ, Ibbotson T, Perry CM. Lamotrigine: a review of its use in bipolar disorder. Drugs 2003; 63 (19): 2029–50. 52. Goodwin GM, Bowden CL, Calabrese JR et al. A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J Clin Psychiatry 2004; 65 (3): 432–41. 53. Greenhill SD, Jones RS. Diverse antiepileptic drugs increase the ratio of background synaptic inhibition to excitation and decrease neuronal excitability in neurones of the rat entorhinal cortex in vitro. Neuroscience 2010; 167 (2): 456–74. 54. Hachad H, Ragueneau-Majlessi I, Levy RH. New antiepileptic drugs: review on drug interactions. Ther Drug Monit 2002; 24: 91–103. 55. Hahn CG, Gyulai L, Baldassano CF et al. The current understanding of lamotrigine as a mood stabilizer. J Clin Psychiatry 2004; 65: 791–804. 56. Hirschfeld R et al. Screening for bipolar disorder in the community. J Clin Psychiat 2003; 64: 53–9. 57. Holmes GL, Frank LM, Sheth RD et al. Lamotrigine monotherapy for newly diagnosed typical absence seizures in children. Epilepsy Res 2008; 82 (2–3): 124–32. 58. Jacob S, Nair AB. An Updated Overview on Therapeutic Drug Monitoring of Recent Antiepileptic Drugs. Drugs R D 2016; 16 (4): 303–16. 59. Johannessen SI, Tomson T. Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed? Clin Pharmacokinet 2006; 45 (11): 1061–75. 60. Jozwiak S, Terczynski A. Open study evaluating lamotrigine efficacy and safety in add-on treatment and consecutive monotherapy in patients with carbamazepine- or valproate-resistant epilepsy. Seizure 2000; 9 (7): 486–92. 61. Kaufman KR, Gerner R. Lamotrigine toxicity secondary to sertraline. Seizure 1998; 7: 163–5. 62. Kayani S, Sirsi D. The safety and tolerability of newer antiepileptic drugs in children and adolescents. J Cent Nerv Syst Dis 2012; 4: 51–63. 63. Ketter TA, Manji HK, Post RM. Potential mechanisms of action of lamotrigine in the treatment of bipolar disorders. J Clin Psychopharmacol 2003; 23 (5): 484–95. 64. Kimbrell T. Neuroimaging of response to lamotrigine and gabapentin. Am Psychiat Ass Meet 1998; p. 149–50. 65. Kotler M, Matar M. Lamotrigine in the treatment of resistant bipolar disorder. Clin Neuropharmacol 1998; 21: 65–7. 66. Kuzniecky R et al. Modulation of cerebral GABA by topiramate, lamotrigine and gabapentin in healthy adults. Neurology 2002; 58: 368–72. 67. Langosch JM. Influence of lamotrigine on synaptic transmission, neuronal excitability and LTP in guinea pig hippocampal slices. Eur Neuropsychopharmacol 1999; 9 (Suppl. 5): S244. 68. Leach JP, Brodie MJ. Lamotrigine: clinical use in antiepileptic drugs. 4th ed. Raven Press, NY, 1995. 69. Leach MJ, Marden CM, Miller AA. Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: II. Neurochemical studies on the mechanism of action. Epilepsia 1986; 27: 490–7. 70. Lee CY, Fu WM, Chen CC et al. Lamotrigine inhibits postsynaptic AMPA receptor and glutamate release in the dentate gyrus. Epilepsia 2008; 49: 888–97. 71. Liu YT, Zhang LL, Huang L, Zeng LN. Lamotrigine monotherapy in children with epilepsy: a systematic review. Article in Chinese. Zhongguo Dang Dai Er Ke Za Zhi 2016; 18 (7): 582–8. 72. Maidment ID. Lamotrigine – an effective mood stabilizer? Ann Pharmacother 1999; 33: 864–7. 73. Malt UF, Fladvad T. Lamotrigine in the treatment of mental disorders. Article in Norwegian. Tidsskr Nor Laegeforen 2001; 121 (12): 1473–7. 74. Martin R. Cognitive effects of topiramate, gabapentin and lamotrigine in healthy young adults. Neurology 1999; 52: 321–7. 75. May TW, Rambeck B, Jurgens U. Influence of oxcarbazepine and methsuximide on lamotrigine concentrations in epileptic patients with and without valproic acid comedication: results of a retrospective study. Ther Drug Monit 1999; 21 (2): 175–81. 76. Meldrium B. Update on the mechanisms of action of antiepileptic drugs. J Epilepsia 1996; 37: 4. 77. Mockenhaupt M. The current understanding of Stevens-Johnson syndrome and toxic epidermal necrolysis. Expert Rev Clin Immunol 2011; 7 (6): 803–13; quiz 814–5. 78. Mullens EL. Clinical experience with lamotrigine monotherapy in adults with newly diagnosed epilepsy. Clin Drug Invest 1998; 16: 125–33. 79. Ng F, Hallam K, Lucas N, Berk M. The role of lamotrigine in the management of bipolar disorder. Neuropsychiatr Dis Treat 2007; 3 (4): 463–74. 80. Nierenberg AA, Ostacher MJ, Calabrese JR et al. Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone. Am J Psychiatry 2006; 163: 210–16. 81. Obrocea G, Dunn R, Frye MA et al. Clinical predictors of response to lamotrigine and gabapentin monotherapy in refractory affective disorders. Biol Psychiatry 2002; 51: 253–60. 82. Pellock JM. Lamotrigine. J Child Neurol 1997; 12: S1. 83. Pennell PB, Hovinga CA. Antiepileptic drug therapy in pregnancy I: gestation-induced effects on AED pharmacokinetics. Int Rev Neurobiol 2008; 83: 227–40. 84. Perucca E. Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age. Clin Pharmacokinet 2006; 45 (4): 351–63. 85. Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol 2006; 61: 246–55. 86. Perucca E. Is there a role for therapeutic drug monitoring of new anticonvulsants? Clin Pharmacokinet 2000; 38 (3): 191–204. 87. Phelps P. Lamotrigine Update. Parts 1 and 2. www.psychopharmacologyinstitute.com 88. Poolos NP, Migliore M, Johnston D. Pharmacological upregulation of h-channels reduces the excitability of pyramidal neuron dendrites. Nat Neurosci 2002; 5: 767–74. 89. Poza JJ. Management of epilepsy in the elderly. Neuropsychiatr Dis Treat 2007; 3 (6): 723–8. 90. Reid JG, Gitlin MJ, Altshuler LL. Lamotrigine in psychiatric disorders. J Clin Psychiatry 2013; 74 (7): 675–84. 91. Sabers A, Buchholt JM, Uldall P et al. Lamotrigine plasma levels reduced by oral contraceptives. Epilepsy Res 2001; 47: 151–4. 92. Sabers A, Gram L. Newer anticonvulsants: comparative review of drug interactions and adverse effects. Drugs 2000; 60 (1): 23–33. 93. Sagud M, Pivac N, Mustapic M et al. The effect of lamotrigine on platelet serotonin concentration in patients with bipolar depression. Psychopharmacology (Berl) 2008; 197 (4): 683–5. 94. Schapel GJ, Beran RG, Vajda FJ et al. Double-blind, placebo controlled, crossover study of lamotrigine in treatment resistant partial seizures. J Neurol Neurosurg Psychiatry 1993; 56 (5): 448–53. 95. Sharma V, Khan M, Corpse C. Role of lamotrigine in the management of treatment-resistant bipolar II depression: a chart review. J Affect Dis 2008; 111 (1): 100–5. 96. Sidhu J, Job S, Singh S et al. The pharmacokinetic and pharmacodynamic consequences of the co-administration of lamotrigine and a combined oral contraceptive in healthy female subjects. Br J Clin Pharmacol 2006; 61: 191–9. 97. Sierra M. Depersonalization: A New Look at a Neglected Syndrome. Cambridge University Press. 1st Ed. 2009. ISBN 978-0521874984. 98. Sondergaard Khinchi M, Nielsen KA et al. Lamotrigine therapeutic thresholds. Seizure 2008; 17 (5): 391–5. 99. Southam E. Lamotrigine inhibits monoamine uptake in vitro and modulates 5-hydroxytryptamine uptake in rats. Eur J Pharmacol 1998; 358: 19–24. 100. Splinter M. Pharmacokinetic properties of new antiepileptic drugs. J Pharm Practice 2005; 18: 444–60. 101. Stahl SM. Stahl’s essential psychopharmacology: neuroscientific basis and practical applications. Cambridge university press, 2013. 102. Stefani A, Spadoni F, Siniscalchi A, Bernardi G. Lamotrigine inhibits Ca2+ currents in cortical neurons: functional implications. Eur J Pharmacol 1996; 307 (1): 113–6. 103. Steiner TJ, Dellaportas CI, Findley LJ et al. Lamotrigine monotherapy in newly diagnosed untreated epilepsy: A double-blind comparison with phenytoin. Epilepsia 1999; 40: 601–7. 104. Sumegi A. Mood stabilizers – past, present and future. Neuropsychopharmacol Hung 2008; 10: 31–42. 105. Tennis P, John A, Messenheimer R. Preliminary result on frequency of mayor malformation following Lamotrigine monotherapy or polytherapy exposure during pregnancy. Neurology 2002, 58 (Suppl. 3). 106. Vajda FJ, Dodd S, Horgan D. Lamotrigine in epilepsy, pregnancy and psychiatry – a drug for all seasons? J Clin Neurosci 2013; 20 (1): 13–6. 107. Van de Vrie-Hoekstra NW, De Vries TW, Van den Berg PB et al. Antiepileptic drug utilization in children from 1997–2005 – a study from the Netherlands. Eur J Clin Pharmacol 2008; 64: 1013–20. 108. Varghese SP, Haith LR, Patton ML et al. Lamotrigine-induced toxic epidermal necrolysis in three patients treated for bipolar disorder. Pharmacotherapy 2006; 26 (5): 699–704. 109. Vieta E, Gunther O, Locklear J et al. Effectiveness of psychotropic medications in the maintenance phase of bipolar disorder: a meta-analysis of randomized controlled trials. Int J Neuropsychopharmacol 2011; 14 (8): 1029–49. 110. Walden J, Schaerer L, Schloesser S et al. An open longitudinal study of patients with bipolar rapid cycling treated with lithium or lamotrigine for mood stabilization. Bipolar Dis 2000; 2: 336–9. 111. Weisler RH, Calabrese JR, Bowden CL et al. Discovery and development of lamotrigine for bipolar disorder: a story of serendipity, clinical observations, risk taking, and persistence. J Affect Dis 2008; 108 (1–2): 1–9. 112. Yasumoto S, Shimizu M, Sato K et al. Lamotrigine monotherapy for newly diagnosed typical absence seizures in children: a multi-center, uncontrolled, open-label study. Brain Dev 2016; 38 (4): 407–13. 113. Yatham LN. Newer anticonvulsants in the treatment of bipolar disorder. J Clin Psychiatry 2004; 65 (Suppl. 10): 28–35. 114. Yerby MS. Quality of life, epilepsy advances, and the evolving role of anticonvulsants in women with epilepsy. Neurology 2000; 55 (5 Suppl. 1): 21–31. 115. Zheng C, Yang K, Liu Q et al. The anticonvulsive drug lamotrigine blocks neuronal {alpha}4{beta}2 nicotinic acetylcholine receptors. J Pharmacol Exp Ther 2010; 335: 401–8. 116. Zona C, Tancredi V, Longone P et al. Neocortical potassium currents are enhanced by the antiepileptic drug lamotrigine. Epilepsia 2002; 43: 685–90.